{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:37:15Z","timestamp":1782603435938,"version":"3.54.5"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"vor","delay-in-days":283,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2021]]},"DOI":"10.6061\/clinics\/2021\/e3286","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T19:27:29Z","timestamp":1634585249000},"page":"e3286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2839-7305","authenticated-orcid":false,"given":"Josef","family":"Finsterer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0694-8674","authenticated-orcid":false,"given":"Fulvio A.","family":"Scorza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7810-4748","authenticated-orcid":false,"given":"Carla A.","family":"Scorza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.6061\/clinics\/2021\/e3286_bib1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s41983-021-00310-7","article-title":"Guillain-Barre syndrome in 220 patients with COVID-19","volume":"57","author":"Finsterer","year":"2021","journal-title":"Egypt J Neurol Psychiatr Neurosurg"},{"issue":"1","key":"10.6061\/clinics\/2021\/e3286_bib2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/ane.13451","article-title":"SARS-CoV-2 vaccines are not free of neurological side effects","volume":"144","author":"Finsterer","year":"2021","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"10.6061\/clinics\/2021\/e3286_bib3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ana.26144","article-title":"Guillain-Barr\u00e9 Syndrome Variant Occurring after SARS-CoV-2 Vaccination","volume":"90","author":"Allen","year":"2021","journal-title":"Ann Neurol"},{"key":"10.6061\/clinics\/2021\/e3286_bib4","article-title":"Exacerbating Guillain-Barr\u00e9 Syndrome Eight Days after Vector-Based COVID-19 Vaccination","volume":"2021","author":"Finsterer","year":"2021","journal-title":"Case Rep Infect Dis"},{"key":"10.6061\/clinics\/2021\/e3286_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.idcr.2021.e01143","article-title":"Guillain-Barr\u00e9 syndrome following the first dose of SARS-CoV-2 vaccine: A temporal occurrence, not a causal association","volume":"24","author":"Ogbebor","year":"2021","journal-title":"IDCases"},{"issue":"2","key":"10.6061\/clinics\/2021\/e3286_bib6","article-title":"Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine","volume":"13","author":"Waheed","year":"2021","journal-title":"Cureus"},{"issue":"2","key":"10.6061\/clinics\/2021\/e3286_bib7","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/ana.26143","article-title":"Guillain-Barr\u00e9 Syndrome following ChAdOx1-S\/nCoV-19 Vaccine","volume":"90","author":"Maramattom","year":"2021","journal-title":"Ann Neurol"},{"key":"10.6061\/clinics\/2021\/e3286_bib8","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000011881","article-title":"Guillain- Barr\u00e9 Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial: Temporal Associations Do Not Imply Causality","author":"M\u00e1rquez Loza","year":"2021","journal-title":"Neurology"},{"issue":"6","key":"10.6061\/clinics\/2021\/e3286_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-242344","article-title":"Trigeminal and cervical radiculitis after tozinameran vaccination against COVID-19","volume":"14","author":"Narasimhalu","year":"2021","journal-title":"BMJ Case Rep"},{"key":"10.6061\/clinics\/2021\/e3286_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.rce.2021.05.005","article-title":"Covid-19, guillain-barr\u00e9 y vacuna. Una mezcla peligrosa [(Covid-19, Guillain-Barr\u00e9 Syndrome, And The Vaccine: A Dangerous Combination]","author":"Aomar-Mill\u00e1n","year":"2021","journal-title":"Rev Clin Esp"},{"issue":"4","key":"10.6061\/clinics\/2021\/e3286_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-242956","article-title":"Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1","volume":"14","author":"Patel","year":"2021","journal-title":"BMJ Case Rep"},{"issue":"23","key":"10.6061\/clinics\/2021\/e3286_bib12","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"10.6061\/clinics\/2021\/e3286_bib13","author":"Medicines and Healthcare products Regulatory Agency"},{"key":"10.6061\/clinics\/2021\/e3286_bib14","author":"VAERS"},{"key":"10.6061\/clinics\/2021\/e3286_bib15","author":"FDA News Release"},{"key":"10.6061\/clinics\/2021\/e3286_bib17","author":"World Health Organization"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222002447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222002447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:51:04Z","timestamp":1761720664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593222002447"},"secondary":[{"URL":"https:\/\/www.scielo.br\/j\/clin\/a\/fdLF9wWj3y8KJ9RvLgCd4NJ\/?lang=en","label":"SCIELO"},{"URL":"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8478139\/","label":"PMC"},{"URL":"https:\/\/www.clinicsjournal.com\/article\/post-sars-cov-2-vaccination-guillain-barre-syndrome-in-19-patients\/","label":"CLINICS"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":16,"alternative-id":["S1807593222002447"],"URL":"https:\/\/doi.org\/10.6061\/clinics\/2021\/e3286","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.6061\/clinics\/2021\/e3286","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 CLINICS. Published by Elsevier Spain","name":"copyright","label":"Copyright"}],"article-number":"e3286"}}